-
Clinical trials do more than inform us whether a drug is effective. They inform us when a drug is effective, in what combinations, in what dosages, and what are the counter indications.
-
We have experienced unprecedented economic effects of the COVID-19 pandemic and social distancing policies. Twenty two million Americans lost jobs in four weeks.
-
Due to coronavirus, governments across the globe are considering and/or are doing something they certainly could not do before: implement mass surveillance programs to track COVID-19 patients.
-
We have yet to record meaningful samples of the general population with regard to the prevalence of coronavirus, the distribution of its outcomes, and the build-up of immunity.
-
The coronavirus crisis will be considered one of the most important global events of the early decades of the 21st century.
-
If the COVID-19 crisis has taught us one thing—aside from the need to wash your hands often—it is that the FDA’s approval process for much-needed medicine to those with debilitating and terminal diseases is in dire need of reform.
-
The United States has taken unprecedented actions to halt the spread of the novel coronavirus and the illness it causes, COVID-19. How bad will this be for the economy?
-
In its first decade, ObamaCare has failed to solve many of the health care problems it was supposed to address.
-
The word has leaked out on a potential cheap treatment for COVID-19, the antimalarial drug hydroxychloroquine.
-
Here’s what Trump should say during his next coronavirus press conference.
-
The stimulus approach fails to address the fundamental causes of the economic downturn, while it balloons the deficit to no good end.
-
A New York Times report on ventilator production misses the point.
-
The vast sums proposed to be spent under dubious national Green New Deals should be spent instead on health care, especially virus prevention and protection.
